India, May 15 -- Silexion Therapeutics Corp. (SLXN) has secured approximately $1 million in gross proceeds following the immediate exercise of previously issued warrants, providing additional working capital as the company advances its RNA interference (RNAi) pipeline targeting KRAS-driven cancers.
The exercised warrants, originally issued in August and September 2025, were repriced to $0.50 per share and cover a total of 1,995,092 ordinary shares. The shares underlying these warrants are registered under effective Form S-3 registration statements.
The transaction is expected to close on or about May 18, 2026, subject to customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent. Silexion plans to use t...